mobocertinib

ASCO 2021 – the exon 20 army lines up behind Rybrevant
EP Vantage
Mon, 06/7/21 - 11:12 am
ASCO 2021
JNJ
Rybrevant
exon 20-insertion NSCLC
Takea
mobocertinib
Dizal Pharmaceutical
Black Diamond Therapeutics
Takeda earns win for its TKI inhibitor in tiny lung cancer group — but GI side effects could be an early red flag
Endpoints
Thu, 01/28/21 - 10:41 am
Takeda
lung cancer
mobocertinib
non-small cell lung cancer
Takeda gets FDA breakthrough therapy status for mobocertinib to treat certain type of lung cancer
Pharmaceutical Business Review
Tue, 04/28/20 - 11:45 pm
Takeda
FDA
mobocertinib
metastatic non-small cell lung cancer